There are around 46,000 new cases of prostate cancer each year in England and Wales, with 13% of these cases showing signs of ...

By doing hormone therapy up front in prostate cancer cases, the hope was to shrink the relapse rate after surgery. Results ...

ADT plus apalutamide before and after surgery significantly improved metastasis-free survi ...

Compared with patients receiving hormone therapy alone, patients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20 percent reduction in the ris ...

High-risk localized and locally advanced prostate cancer patients treated with apalutamide—a next generation neoadjuvant androgen-receptor pathway inhibitor (ARPI)—plus hormone therapy before and ...

Adding apalutamide to ADT in the adjuvant and neoadjuvant settings improves outcomes in prostate cancer patients undergoing ...

Top urologists debunk prostate cancer myths, explain PSA testing, screening guidelines, risk factors, symptoms, and the ...